Az ovarialis hiperstimulációs szindróma kórélettana és korszerű klinikuma

Translated title of the contribution: Pathophysiology and current clinical approach of ovarian hyperstimulation syndrome

Szabó Gábor, Árokszállási Anikó, Pócsi Dóra, Murber Ákos, Urbancsek János, J. Rigó

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

During assisted reproduction technologies, controlled hyperstimulation of the ovaries occurs. Ovarian hyperstimulation syndrome is an excessive overreaction of the ovaries complicating pharmacological ovulation induction. Rarely other causes, such as the mutation of the follicle-stimulating hormone receptor may also be in the background. Ovarian hyperstimulation syndrome is clinically characterized by a massive ovarian enlargement associated with an acute third-space fluid shift responsible for the development of ascites, and sometimes pleural or pericardial effusion. Associated arterial or venous thromboembolic symptoms are also common. Ovarian hyperstimulation syndrome is an iatrogenic and potentially life-threatening condition in the form of ischemic stroke or circulatory insufficiency of the limbs. Recently some new methods have been developed for the prevention of the disease. The syndrome affects young, healthy patients. It also has an important economic burden due to the absence from work, bed rest, or hospitalization and intensive medical management of more severe cases. Supportive therapy, anticoagulant prophylaxis and close monitoring are the main approach for the syndrome. However, hospitalization or intervention should not be delayed for patients with severe or critical conditions.

Original languageHungarian
Pages (from-to)1390-1398
Number of pages9
JournalOrvosi Hetilap
Volume159
Issue number34
DOIs
Publication statusPublished - Aug 1 2018

Fingerprint

Ovarian Hyperstimulation Syndrome
Ovary
Hospitalization
Fluid Shifts
FSH Receptors
Bed Rest
Pericardial Effusion
Ovulation Induction
Pleural Effusion
Ascites
Anticoagulants
Reproduction
Extremities
Stroke
Economics
Pharmacology
Technology
Mutation
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Az ovarialis hiperstimulációs szindróma kórélettana és korszerű klinikuma. / Gábor, Szabó; Anikó, Árokszállási; Dóra, Pócsi; Ákos, Murber; János, Urbancsek; Rigó, J.

In: Orvosi Hetilap, Vol. 159, No. 34, 01.08.2018, p. 1390-1398.

Research output: Contribution to journalArticle

Gábor, S, Anikó, Á, Dóra, P, Ákos, M, János, U & Rigó, J 2018, 'Az ovarialis hiperstimulációs szindróma kórélettana és korszerű klinikuma', Orvosi Hetilap, vol. 159, no. 34, pp. 1390-1398. https://doi.org/10.1556/650.2018.31152
Gábor, Szabó ; Anikó, Árokszállási ; Dóra, Pócsi ; Ákos, Murber ; János, Urbancsek ; Rigó, J. / Az ovarialis hiperstimulációs szindróma kórélettana és korszerű klinikuma. In: Orvosi Hetilap. 2018 ; Vol. 159, No. 34. pp. 1390-1398.
@article{e48e558b2787445795ebcf6e15e9a74e,
title = "Az ovarialis hiperstimul{\'a}ci{\'o}s szindr{\'o}ma k{\'o}r{\'e}lettana {\'e}s korszerű klinikuma",
abstract = "During assisted reproduction technologies, controlled hyperstimulation of the ovaries occurs. Ovarian hyperstimulation syndrome is an excessive overreaction of the ovaries complicating pharmacological ovulation induction. Rarely other causes, such as the mutation of the follicle-stimulating hormone receptor may also be in the background. Ovarian hyperstimulation syndrome is clinically characterized by a massive ovarian enlargement associated with an acute third-space fluid shift responsible for the development of ascites, and sometimes pleural or pericardial effusion. Associated arterial or venous thromboembolic symptoms are also common. Ovarian hyperstimulation syndrome is an iatrogenic and potentially life-threatening condition in the form of ischemic stroke or circulatory insufficiency of the limbs. Recently some new methods have been developed for the prevention of the disease. The syndrome affects young, healthy patients. It also has an important economic burden due to the absence from work, bed rest, or hospitalization and intensive medical management of more severe cases. Supportive therapy, anticoagulant prophylaxis and close monitoring are the main approach for the syndrome. However, hospitalization or intervention should not be delayed for patients with severe or critical conditions.",
keywords = "Intensive care, Ovarian hyperstimulation syndrome, Prevention, Ultrasound imaging",
author = "Szab{\'o} G{\'a}bor and {\'A}roksz{\'a}ll{\'a}si Anik{\'o} and P{\'o}csi D{\'o}ra and Murber {\'A}kos and Urbancsek J{\'a}nos and J. Rig{\'o}",
year = "2018",
month = "8",
day = "1",
doi = "10.1556/650.2018.31152",
language = "Hungarian",
volume = "159",
pages = "1390--1398",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "34",

}

TY - JOUR

T1 - Az ovarialis hiperstimulációs szindróma kórélettana és korszerű klinikuma

AU - Gábor, Szabó

AU - Anikó, Árokszállási

AU - Dóra, Pócsi

AU - Ákos, Murber

AU - János, Urbancsek

AU - Rigó, J.

PY - 2018/8/1

Y1 - 2018/8/1

N2 - During assisted reproduction technologies, controlled hyperstimulation of the ovaries occurs. Ovarian hyperstimulation syndrome is an excessive overreaction of the ovaries complicating pharmacological ovulation induction. Rarely other causes, such as the mutation of the follicle-stimulating hormone receptor may also be in the background. Ovarian hyperstimulation syndrome is clinically characterized by a massive ovarian enlargement associated with an acute third-space fluid shift responsible for the development of ascites, and sometimes pleural or pericardial effusion. Associated arterial or venous thromboembolic symptoms are also common. Ovarian hyperstimulation syndrome is an iatrogenic and potentially life-threatening condition in the form of ischemic stroke or circulatory insufficiency of the limbs. Recently some new methods have been developed for the prevention of the disease. The syndrome affects young, healthy patients. It also has an important economic burden due to the absence from work, bed rest, or hospitalization and intensive medical management of more severe cases. Supportive therapy, anticoagulant prophylaxis and close monitoring are the main approach for the syndrome. However, hospitalization or intervention should not be delayed for patients with severe or critical conditions.

AB - During assisted reproduction technologies, controlled hyperstimulation of the ovaries occurs. Ovarian hyperstimulation syndrome is an excessive overreaction of the ovaries complicating pharmacological ovulation induction. Rarely other causes, such as the mutation of the follicle-stimulating hormone receptor may also be in the background. Ovarian hyperstimulation syndrome is clinically characterized by a massive ovarian enlargement associated with an acute third-space fluid shift responsible for the development of ascites, and sometimes pleural or pericardial effusion. Associated arterial or venous thromboembolic symptoms are also common. Ovarian hyperstimulation syndrome is an iatrogenic and potentially life-threatening condition in the form of ischemic stroke or circulatory insufficiency of the limbs. Recently some new methods have been developed for the prevention of the disease. The syndrome affects young, healthy patients. It also has an important economic burden due to the absence from work, bed rest, or hospitalization and intensive medical management of more severe cases. Supportive therapy, anticoagulant prophylaxis and close monitoring are the main approach for the syndrome. However, hospitalization or intervention should not be delayed for patients with severe or critical conditions.

KW - Intensive care

KW - Ovarian hyperstimulation syndrome

KW - Prevention

KW - Ultrasound imaging

UR - http://www.scopus.com/inward/record.url?scp=85052001403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052001403&partnerID=8YFLogxK

U2 - 10.1556/650.2018.31152

DO - 10.1556/650.2018.31152

M3 - Article

C2 - 30122058

AN - SCOPUS:85052001403

VL - 159

SP - 1390

EP - 1398

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 34

ER -